-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Stavudine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/3056-17-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 3056-17-5 |
| Description | Stavudine (d4T) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV. |
Product Information
| Synonyms | 2',3'-Dideoxy-2',3'-didehydrothymidine; D4T; 3'-Deoxy-2'-thymidinene; 3'-Deoxy-2',3'-didehydrothymidine; BMY-27857; Zerit; NSC 163661; Sanilvudine; Virostav; Zidovudine EP Impurity A; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine |
| IUPAC Name | 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione |
| Molecular Weight | 224.21 |
| Molecular Formula | C10H12N2O4 |
| Canonical SMILES | CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO |
| InChI | InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1 |
| InChIKey | XNKLLVCARDGLGL-JGVFFNPUSA-N |
| Boiling Point | 440.6±55.0 °C at 760 mmHg |
| Melting Point | 158-160°C |
| Flash Point | 220.3±31.5 °C |
| Purity | ≥95% |
| Density | 1.374±0.06 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
| Appearance | White to Off-white Solid |
| Application | Anti-HIV Agents |
| Storage | Store at -20°C |
| Complexity | 388 |
| Exact Mass | 224.07970687 |
| Index Of Refraction | 1.646 |
| In Vitro | Stavudine (d4T) (50 μM) significantly reduces the expression of the NLRP3 inflammasome gene, IL-18 production and Aβ 42-stimulated cellular production of IL-1β in THP-1 derived macrophages. Stavudine (d4T) (50 μM) inhibits the assembly of the NLRP3 inflammasome complex and down-regulates the phagocytosis of Aβ 42 by macrophages. Stavudine (d4T) (10 μM, 7 or 14 days) significantly induced CEM cells Apoptosis, especially after 14 days, and increases hydrogen peroxide levels. |
| In Vivo | Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes. |
| PSA | 84.32000 |
| Target | Reverse Transcriptase; HIV; Nucleoside Antimetabolite/Analog; NOD-like Receptor (NLR); Autophagy; Apoptosis |
| Vapor Pressure | 0.0±2.4 mmHg at 25°C |
| XLogP3-AA | -0.8 |
